AOD-9604

Overview

AOD-9604 is a synthetic peptide analog of the C-terminal fragment of human growth hormone. Developed by Monash University, it mimics GH's fat-burning effects while avoiding the risks associated with full GH therapy — no impact on blood sugar, IGF-1, or growth.

Key Benefits

• Targeted Fat Loss: Stimulates lipolysis specifically in adipose tissue
• No IGF-1 Increase: Doesn't raise IGF-1 or promote tissue growth
• No Glucose Impact: Unlike GH, does not cause insulin resistance
• Cartilage Repair: Emerging evidence for osteoarthritis treatment
• Favorable Safety: TGA-approved in Australia for human use

AOD-9604 vs HGH

Full growth hormone causes lipolysis but also raises IGF-1, can worsen insulin resistance, and promotes tissue growth. AOD-9604 isolates the fat-metabolizing mechanism without these side effects, making it safer for long-term use.

Mechanism of Action

AOD-9604 mimics the lipolytic action of the C-terminal fragment of GH by activating beta-3 adrenergic receptors on adipocytes. It stimulates lipolysis and inhibits lipogenesis without binding to the GH receptor, meaning no IGF-1 elevation or growth-promoting effects.

Research Status

Phase II/III clinical trials completed. TGA-approved in Australia. GRAS status granted by FDA for food use. Active research for osteoarthritis.

Safety Profile

Excellent safety profile. No significant adverse effects in clinical trials. No impact on glucose, IGF-1, or cortisol. Injection site reactions possible. Well-tolerated in long-term studies.

Related Compounds